Furthermore, with growing data supporting the pathogenic role of the IL-23/Th17 axis in IBD [31,72] and with DCs being the main source of IL-23, it is becoming evident that the suppression of the microbial determinants triggering this deleterious inflammatory process in DCs, while restoring the eubiotic composition of the gut microbiota, may be an attractive therapeutic strategy in IBD [73]. The gene discussed is IL23A; the disease is inflammatory bowel disease.